What’s Coming July 23rd: The FDA’s Big Peptide Meeting

On July 23rd and 24th, the FDA is holding a critical meeting that could decide the future of peptide access in America.

In this episode, I break down what’s at stake with 7 major peptides under review: BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon.

We discuss why the FDA is pushing back, whether patent issues and money are playing a role, and what this could mean for compounding pharmacies and patients.

This is one of the most important weeks coming up for the peptide community.

Watch until the end for my final thoughts.

Previous episode on FDA transparency: click here

Subscribe for more biohacking tips, rate us 5 stars, and join The Human 5.0 Project community for exclusive upgrades. Drop your peptide and longevity stories in the comments!

Follow on IG @Ultimatebiohacker10X

For more longevity insights and protocols, check out biohackerdepot.com – your go-to resource for cutting-edge health optimization strategies.

And if you're sourcing research peptides , peptidesphere.com has a curated selection of peptides and bioregulators with detailed info on quality and applications.